Hayashi et al

Hayashi et al

Hayashi et al. kinase inhibitors (TKIs) imatinib, nilotinib, and dasatinib are utilized as first-line treatment in CML. These little molecule inhibitors stop the adenosine triphosphate-binding site from the Bcr-Abl tyrosine kinase and stop phosphorylation of downstream effector Desmethyldoxepin HCl proteins. Medical response to treatment can